Bo Li

Dr. Bo Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in International Journal of Surgery
Verified
Journal Article
Open access
DLDe Luo
De Luo
XCXin-Pei Chen
Xin-Pei Chen
YDYang Dai
Yang Dai
FKFei Kuang
Fei Kuang
MKMao-Ji Kang
Mao-Ji Kang
SSSong Su
Song Su
Background: There is still a lack of knowledge on the association between cholecystectomy and liver disease. This systematic review and meta-analysis was conducted to summarize the available evidence on the association of cholecystectomy with liver disease and quantify the magnitude of the risk of liver disease after cholecystectomy. Methods: PubMed, Embase, Web of Science, and Cochrane Library were searched systematically from database inception to January 2023 to identify eligible studies that evaluated the association between cholecystectomy and the risk of liver disease. Meta-analysis was conducted to obtain a summary odds ratio (OR) and 95% confidence interval (CI) using a random-effects model. Results: We identified 20 studies with a total of 27,320,709 individuals and 283,633 liver disease cases. Cholecystectomy was associated with an increased risk of liver disease (OR 1.63, 95% CI 1.34-1.98). In particular, cholecystectomy was found to be significantly associated with a 54% increased risk of nonalcoholic fatty liver disease (OR 1.54, 95% CI 1.18-2.01), a 173% increased risk of cirrhosis (OR 2.73, 95% CI 1.81-4.12), and a 46% increased risk of primary liver cancer (OR 1.46, 95% CI 1.18-1.82). Conclusions: There is an association between cholecystectomy and the risk of liver disease. Our results suggest that strict surgical indications should be implemented to reduce unnecessary cholecystectomy. Additionally, the routine assessment of liver disease is necessary for patients with a history of cholecystectomy. More prospective large-sample studies are required for better estimates of the risk. Export

15 May 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
QHQingwen Hu
Qingwen Hu
JCJiali Chen
Jiali Chen
YLYang Liu
Yang Liu
HCHaiqing Chen
Haiqing Chen
HLHaotian Lai
Haotian Lai
XZXiaolin Zhong
Xiaolin Zhong
Background: Pancreatic cancer (PC) is a highly aggressive pancreatic malignant tumor with poor prognosis due to its complex tumor microenvironment (TME) and metastatic potential. Fibroblasts play an important role in tumor progression and metastasis by remodeling the extracellular matrix (ECM) and influencing the immune response. This study explored migrasome-associated fibroblasts, especially TSPAN4 and ITGA5, as key regulators of pancreatic cancer metastasis, aiming to provide new ideas for therapeutic strategies targeting TME.Methods: We employed single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics to analyze pancreatic cancer tissues. Data from the GEO and TCGA databases were integrated and processed using batch correction techniques. Single-cell data were analyzed with Seurat and Monocle for dimensionality reduction and pseudotime trajectory analysis. Cell communication was assessed using CellCall and CellChat. Spatial transcriptomic analysis was conducted with RCTD and MISTy tools to investigate cell interactions within the TME. Additionally, gene enrichment, deconvolution, and prognostic analyses were performed, alongside experimental validation through siRNA transfection, qRT-PCR, and various functional assays to investigate the role of TSPAN4 in metastasis.Results: Our results underscore the critical role of TSPAN4+ fibroblasts in pancreatic cancer. These fibroblasts were predominantly located at the tumor periphery and exhibited elevated migrasome gene expression, which was associated with enhanced ECM remodeling and immune suppression. Intercellular communication analysis revealed that TSPAN4+ fibroblasts engaged in extensive interactions with immune cells, such as macrophages and endothelial cells, facilitating metastasis and immune evasion. Moreover, the high expression of immune checkpoint markers indicated their involvement in modulating the immune response.Conclusion: TSPAN4+ fibroblasts are key regulators of pancreatic cancer progression, contributing to metastasis, immune suppression, and ECM remodeling. Targeting these fibroblasts represents a promising therapeutic strategy to improve clinical outcomes and enhance the effectiveness of immunotherapies in pancreatic cancer.

14 September 2022 in Liver International
Verified
Journal Article
Closed access
DLDe Luo
De Luo
XCXinpei Chen
Xinpei Chen
JDJuan Du
Juan Du
BMBingjie Mei
Bingjie Mei
AWAnkang Wang
Ankang Wang
SSSu Song
Su Song

1 November 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YGYu Gong
Yu Gong
DGDesheng Gong
Desheng Gong
SLSinian Liu
Sinian Liu
XGXiangjin Gong
Xiangjin Gong
JXJingwen Xiong
Jingwen Xiong
BLBo Li
Bo Li
Pancreatic cancer (PC) is a very aggressive digestive system tumor, known for its high mortality rate, low cure rate, low survival rate and poor prognosis. In particular, pancreatic ductal adenocarcinoma (PADC), which accounts for more than 90% of PC cases, has an overall 5-year survival rate of only 5%, which is an extremely critical situation. Early detection and effective treatment of PC is extremely difficult, which leads many patients to despair. In the current medical context, targeted therapy, as an important strategy for cancer treatment, is expected. However, the problems of immune escape and drug resistance in PC have become two major obstacles that are difficult to be overcome by targeted therapy. How to break through these two difficulties has become a key issue to be solved in the field of PC therapy. In recent years, non-coding RNAs (ncRNAs) have continued to heat up in the field of cancer research. NcRNAs play a pivotal role in gene regulation, cell differentiation, development, and disease processes, and their important roles in the genesis, development, and therapeutic response of PC have been gradually revealed. More importantly, ncRNAs have many advantages as therapeutic targets, such as high specificity and low side effects, making them a new favorite in the field of PC therapy. Therefore, the aim of this paper is to provide new ideas and methods for the targeted therapy of PC by reviewing the mechanism of action of four major ncRNAs (circRNAs, lncRNAs, miRNAs, siRNAs) in both immune escape and drug resistance of PC. It is expected that an effective way to overcome immune escape and drug resistance can be found through in-depth study of ncRNA, bringing a ray of hope to PC patients.